EpiPen Price Increases Were Made Worse by the Fact That You Can’t Buy Just One
September 7, 2016
By: Emma Court
MarketWatch
Axinn partner Thomas Rohback was quoted in the Market Watch article, "EpiPen Price Increases Were Made Worse by the Fact That You Can’t Buy Just One."
Click here to access the article.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ABA White Collar Crime Institute 2026
Speaking Engagement
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
Noerr Competition Day 2026
Speaking Engagement
Antitrust
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
University of Pennsylvania Journal of Business Law Annual Symposium 2026
Speaking Engagement
Antitrust
CLA Antitrust and Consumer Protection Section In-House Counsel Summit
Speaking Engagement
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
Axinn Receives Multiple LCLD Awards; Announces 2026 Fellows and Pathfinders
Workplace Culture & Opportunity
Axinn Secures Multiple Shortlists for 2026 Global Competition Review Awards
Awards & Recognitions
Antitrust
